PBLA
Income statement / Annual
Last year (2023), Panbela Therapeutics, Inc.'s total revenue was $0.00,
and the percentage change from the previous year is not available.
In 2023, Panbela Therapeutics, Inc.'s net income was -$25.26 M.
See Panbela Therapeutics, Inc.,s key income statements, including revenue, expenses, profit, and income.
| Period |
FY-2023
|
FY-2022
|
FY-2021
|
FY-2020
|
FY-2019
|
FY-2018
|
FY-2017
|
FY-2016
|
FY-2015
|
FY-2014
|
| Period Ended |
12/31/2023 |
12/31/2022 |
12/31/2021 |
12/31/2020 |
12/31/2019 |
12/31/2018 |
12/31/2017 |
12/31/2016 |
12/31/2015 |
12/31/2014 |
| Operating Revenue |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$1.36 M |
| Cost of Revenue |
$25.65 M
|
$35.73 M
|
$10.01 M
|
$5.75 M
|
$4.32 M
|
$3.89 M
|
$6.02 M
|
$5.17 M
|
$5.44 M
|
$595.15 K
|
| Gross Profit |
-$25.65 M
|
-$35.73 M
|
-$10.01 M
|
-$5.75 M
|
-$4.32 M
|
-$3.89 M
|
-$6.02 M
|
-$5.17 M
|
-$5.44 M
|
$761.84 K
|
| Gross Profit Ratio |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0.56
|
| Research and Development Expenses |
$20.61 M
|
$28.05 M
|
$5.42 M
|
$2.51 M
|
$2.35 M
|
$1.78 M
|
$2.59 M
|
$2.50 M
|
$2.85 M
|
$2.37 K
|
| General & Administrative Expenses |
$5.03 M
|
$6.04 M
|
$4.59 M
|
$3.25 M
|
$1.97 M
|
$2.11 M
|
$3.42 M
|
$2.66 M
|
$2.81 M
|
$837.24 K
|
| Selling & Marketing Expenses |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
-$217.00 K
|
$0.00
|
| Selling, General & Administrative Expenses |
$5.03 M
|
$6.04 M
|
$4.59 M
|
$3.25 M
|
$1.97 M
|
$2.11 M
|
$3.42 M
|
$2.66 M
|
$2.59 M
|
$837.24 K
|
| Other Expenses |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
-$508.00 K
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Operating Expenses |
$25.65 M
|
$34.09 M
|
$10.01 M
|
$5.75 M
|
$4.32 M
|
$3.84 M
|
$6.02 M
|
$5.17 M
|
$5.44 M
|
$837.24 K
|
| Cost And Expenses |
$51.29 M
|
$16.36 M
|
$10.01 M
|
$5.75 M
|
$4.32 M
|
$3.84 M
|
$6.02 M
|
$5.17 M
|
$5.44 M
|
$1.43 M
|
| Interest Income |
$123.00 K
|
$14.00 K
|
$1.00 K
|
$17.00
|
$2.19 K
|
$0.00
|
$1.00 K
|
$2.00 K
|
$8.00 K
|
$4.00 K
|
| Interest Expense |
-$317.00 K
|
$288.00 K
|
$11.00 K
|
$17.00 K
|
$2.19 M
|
$1.81 M
|
$1.62 M
|
$180.00 K
|
$183.00 K
|
$35.53 K
|
| Depreciation & Amortization |
-$25.53 M
|
$16.36 K
|
$10.01 K
|
$0.00
|
$4.32 K
|
$3.89 K
|
$6.02 K
|
$5.17 K
|
$8.00 K
|
$9.58 K
|
| EBITDA |
-$51.29 M |
-$34.74 M |
-$10.61 M |
-$5.05 M |
-$4.42 M |
-$1.76 M |
-$6.02 M |
-$5.17 M |
-$5.12 M |
-$75.40 K |
| EBITDA Ratio |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
-0.06
|
| Operating Income Ratio |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
-0.06
|
| Total Other Income/Expenses Net |
$25.85 M
|
-$956.00 K
|
-$613.00 K
|
$691.00 K
|
-$2.29 M
|
-$2.27 M
|
-$4.89 M
|
-$285.00 K
|
-$564.00 K
|
-$31.53 K
|
| Income Before Tax |
-$25.45 M
|
-$35.05 M
|
-$10.62 M
|
-$5.06 M
|
-$6.62 M
|
-$6.16 M
|
-$10.91 M
|
-$5.45 M
|
-$5.68 M
|
-$106.92 K
|
| Income Before Tax Ratio |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
-0.08
|
| Income Tax Expense |
-$186.00 K
|
-$116.00 K
|
-$488.00 K
|
-$295.00 K
|
-$415.00 K
|
-$254.00 K
|
-$536.00 K
|
-$341.00 K
|
-$756.00 K
|
$121.00
|
| Net Income |
-$25.26 M
|
-$34.93 M
|
-$10.14 M
|
-$4.77 M
|
-$6.20 M
|
-$5.91 M
|
-$10.37 M
|
-$5.11 M
|
-$4.93 M
|
-$107.04 K
|
| Net Income Ratio |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
-0.08
|
| EPS |
-232429.55 |
-40748.57 |
-20773.7 |
-14798.1 |
-26103.83 |
-1519.95 |
-3491.75 |
-1974.51 |
-4203.92 |
-892.03 |
| EPS Diluted |
-232429.55 |
-40748.57 |
-20773.7 |
-14798.1 |
-26103.83 |
-1519.95 |
-3491.75 |
-1974.51 |
-4203.92 |
-892.03 |
| Weighted Average Shares Out |
$108.69
|
$857.28
|
$487.88
|
$322.20
|
$237.51
|
$3.89 K
|
$2.97 K
|
$2.59 K
|
$1.17 K
|
$120.00
|
| Weighted Average Shares Out Diluted |
$108.69
|
$857.28
|
$487.88
|
$322.20
|
$237.51
|
$3.89 K
|
$2.97 K
|
$2.59 K
|
$1.17 K
|
$120.00
|
| Link |
|
|
|
|
|
|
|
|
|
|
